ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - powder and solvent for solution for injection - meningococcal vaccines group y 5 mcg / 0.5 ml; meningococcal vaccines group w 5 mcg / 0.5 ml; meningococcal vaccines group c 5 mcg / 0.5 ml; meningococcal vaccines group a 10 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - meningococcus b, multicomponent vaccine; meningococcus b, multicomponent vaccine - תרחיף להזרקה - meningococcus b, multicomponent vaccine 60 mcg; meningococcus b, multicomponent vaccine 60 mcg - meningococcus b, multicomponent vaccine

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - אבקה וממס להכנת תרחיף להזרקה - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn or 69 kda omp); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml; diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid vaccine 8 mcg / 0.5 ml; inactivated polio virus (ipv) type 3 32 du / 0.5 ml; inactivated polio virus (ipv) type 1 40 du / 0.5 ml; inactivated polio virus (ipv) type 2 8 du / 0.5 ml - bacterial and viral vaccines, combined - for booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of four years onwards. boostrix polio is not intended for primary immunisation. the administration of boostrix polio should be based on official recommendations.

ישראל - עברית - Ministry of Health

sanofi israel ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - תמיסה להזרקה - meningococcal vaccines group c 4 mcg / 0.5 ml; meningococcal vaccines group y 4 mcg / 0.5 ml; meningococcal vaccines group w 4 mcg / 0.5 ml; meningococcal vaccines group a 4 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - active immunization of individuals 9 mouths through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.

ישראל - עברית - Ministry of Health

medici medical ltd, israel - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; poliovirus type 1; poliovirus type 2; poliovirus type 3; prp of haemophilus infl. type b; tetanus toxoid - תרחיף להזרקה - pertactin (prn) 3 mcg ml; diphtheria toxoid 15 lf ml; tetanus toxoid 5 lf ml; pertussis toxoid vaccine 20 mcg ml; filamentous haemagglutinin (fha) 20 mcg ml; fimbrae tupes 2 + 3 (fim) 5 mcg ml; poliovirus type 1 40 du ml; poliovirus type 2 8 du ml; poliovirus type 3 32 du ml; prp of haemophilus infl. type b 10 mcg ml - bacterial and viral vaccines, combined - pediacel is indicated for immunization of children at or above the age of 2 months and as a booster in children up to their 7th birthday against diphtheria, tetanus, whooping cough, poliomyelitis and invasive haemophilus influenzae type b disease. in infants, three infectons are to be given intramuscularly at 2, 4 and 6 months of age followed by a booster at 18 months of age. children who have had pertusis, tetanus, diphtheria or haemophilus influenzae type b invasive disease should still be immunized since these clinical infections do not always confer immunity. children who have had natural pertussis can continue to receive pertussis - containing vaccines. human immunodeficiency virus (hiv) infected persons hiv- infected individuals, both asymptomatic and symptomatic, should be immunized with pediacel vaccine according to standard schedules.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - תרחיף להזרקה - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine